EWA
MAZE

EverSource Wealth Advisors’s Maze Therapeutics MAZE Stock Holding History

EverSource Wealth Advisors’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.45K Sell
149
-54
-27% -$1.42K ﹤0.01% 3343
2026
Q1 		$6.06K Buy
203
+54
+36% +$2.38K ﹤0.01% 3172
2025
Q4 		$6.17K Hold
149
– – ﹤0.01% 3032
2025
Q3 		$3.86K Buy
149
+35
+31% +$591 ﹤0.01% 3264
2025
Q2 		$1.4K Buy
+114
New +$1.19K ﹤0.01% 3628

Other funds holding MAZE

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
FWP
Falcon Wealth Planning Ontario, California $1.58B AUM 20.99% 1-Year Est. Return

EverSource Wealth Advisors's MAZE Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Maze Therapeutics (MAZE) stake by 27% in Q2 2026, selling an estimated $1.42K and leaving 149 shares worth $4.45K. The position accounts for ﹤0.01% of the portfolio, ranked #3343.

EverSource Wealth Advisors first reported a position in MAZE in Q2 2025 and has held it in 5 quarters since. The position peaked at $6.17K in Q4 2025. 22 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • EverSource Wealth Advisors held 149 shares of Maze Therapeutics worth $4.45K as of Q2 2026.
  • EverSource Wealth Advisors sold 54 Maze Therapeutics shares in Q2 2026, an estimated $1.42K.
  • Maze Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3343 holding.
  • EverSource Wealth Advisors first reported a position in Maze Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • EverSource Wealth Advisors's Maze Therapeutics position peaked at $6.17K in Q4 2025.
  • 22 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.